Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients

Authors:

Abstract
Background Unintentional weight loss occurs among advanced non-small cell lung cancer (NSCLC) patients and is associated with worse survival. Small studies have suggested that weight gain during treatment is associated with superior survival. Patients and Methods A retrospective analysis analyzed data from three international phase III studies comprising 2301 advanced, nonsquamous NSCLC patients who received a platinum-based, first-line doublet, with or without bevacizumab and maintenance therapy. Body weight was recorded before and after treatment by each study's schedule. The relationship between weight gain and overall survival (OS) and progression-free survival (PFS) was assessed using log-rank test and adjusted Cox modeling. Logistic regression assessed the association between baseline covariates and post-baseline weight gain. Results 421 (18.3%) patients had >5% weight gain after baseline. More than half of the weight gain cohort exhibited initial weight gain by 3 weeks. Median OS was 16.7 months versus 10.7 months for the >5% versus ≤5% weight gain subgroup (N=1880) (pConclusions Weight gain during treatment may be an early indicator of clinical benefit. If confirmed in prospective studies, monitoring weight change may provide important information regarding survival outcomes in NSCLC and may provide ideas for new therapeutic strategies.
Funding Information
  • Eli Lilly and Company

This publication has 23 references indexed in Scilit: